Eliza B Geer

TL;DR: Examination of techniques, results, and side effects of surgery, radiotherapy, and medical therapy, and how advances in technology and novel techniques have changed the way these modalities have changed, emphasize how best to implement available treatment options as part of a multidisciplinary approach at Pituitary Tumor Centers of Excellence.

TL;DR: Long-acting pasireotide is an efficacious treatment option for some patients with Cushing's disease who have persistent or recurrent disease after initial surgery or are not surgical candidates, and provides a convenient monthly administration schedule.

TL;DR: Combination treatment with ipilimumab and nivolumab may be an effective treatment in pituitary carcinoma and identify the development of therapy-induced somatic hypermutation, which may be associated with treatment response to immunotherapy.

TL;DR: In this paper, the efficacy and safety of Levoketoconazole in patients with endogenous Cushing's syndrome were investigated in a phase 3, multicentre, open-label, non-randomised, single-arm study in which they recruited adults (≥18 years) with confirmed Cushing syndrome and a mean 24-h urinary free cortisol (mUFC) of at least 1·5 times the upper limit of normal from 60 hospital and community sites in 19 countries in Europe, and Canada, Israel, Turkey, and the USA.

TL;DR: The data suggest that corticotroph tumors may be categorized into a USP8-mutated, genome-stable subtype versus a USp8-WT, genome -disrupted subtype, the latter of which has a TP53-mutation subtype with high level of chromosome instability.